The antihyperglycemic drug metformin and the thrombocyte aggregation inhibitor dipyridamole are often used concomitantly in patients with diabetes who have suffered a transient ischemic attack or stroke. It has recently been suggested that the gastrointestinal absorption of metformin is mediated by the equilibrative nucleoside transporter 4 (hENT4). Dipyridamole has been reported to inhibit hENT4 transport in vitro. The aim of this research proposal is to study the pharmacokinetic interaction between metformin and dipyridamole. The investigators hypothesize that dipyridamole reduces the gastrointestinal absorption of metformin. If this hypothesis can be confirmed, then the results of this study can explain in part the high variability in plasma metformin concentrations in patients treated with diabetes, and can be used to optimize pharmacotherapy in patients with diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
18
Metformin 500 mg twice daily for four days Dipyridamole 200 mg twice daily for four days
Metformin 500 mg twice daily for four days
Radboud University Nijmegen Medical Centre
Nijmegen, Gelderland, Netherlands
The area under the curve of the metformin plasma concentration at several timepoints
The area under the curve of the metformin plasma concentration at t=0, t=1, t=2, t=2.5, t=3, t=3.5, t=4, t=5, t=6, t=8, and t=10 hours after the intake and the Cmax.
Time frame: 10 hours after ingestion of last dose of metformin
Peak plasma concentration (Cmax) of metformin
Peak plasma concentration (Cmax) of metformin
Time frame: about 3 hours after intake of last dose of metformin
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.